265 related articles for article (PubMed ID: 29674318)
1.
Kytidou K; Beekwilder J; Artola M; van Meel E; Wilbers RHP; Moolenaar GF; Goosen N; Ferraz MJ; Katzy R; Voskamp P; Florea BI; Hokke CH; Overkleeft HS; Schots A; Bosch D; Pannu N; Aerts JMFG
J Biol Chem; 2018 Jun; 293(26):10042-10058. PubMed ID: 29674318
[TBL] [Abstract][Full Text] [Related]
2. Human Alpha Galactosidases Transiently Produced in
Kytidou K; Beenakker TJM; Westerhof LB; Hokke CH; Moolenaar GF; Goosen N; Mirzaian M; Ferraz MJ; de Geus M; Kallemeijn WW; Overkleeft HS; Boot RG; Schots A; Bosch D; Aerts JMFG
Front Plant Sci; 2017; 8():1026. PubMed ID: 28680430
[TBL] [Abstract][Full Text] [Related]
3. Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and the human recombinant alpha-galactosidase A in cultured fibroblasts from patients with Fabry disease.
Porto C; Pisani A; Rosa M; Acampora E; Avolio V; Tuzzi MR; Visciano B; Gagliardo C; Materazzi S; la Marca G; Andria G; Parenti G
J Inherit Metab Dis; 2012 May; 35(3):513-20. PubMed ID: 22187137
[TBL] [Abstract][Full Text] [Related]
4. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients.
Kugadas A; Artoni P; Ruangsiriluk W; Zhao M; Boukharov N; Islam R; Volfson D; Derakhchan K
PLoS One; 2024; 19(5):e0304415. PubMed ID: 38820517
[TBL] [Abstract][Full Text] [Related]
5. Systematic gene therapy derived from an investigative study of AAV2/8 vector gene therapy for Fabry disease.
Deng M; Zhou H; He S; Qiu H; Wang Y; Zhao AY; Mu Y; Li F; Zhao AZ
Orphanet J Rare Dis; 2023 Sep; 18(1):275. PubMed ID: 37670350
[TBL] [Abstract][Full Text] [Related]
6. Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.
Labilloy A; Youker RT; Bruns JR; Kukic I; Kiselyov K; Halfter W; Finegold D; do Monte SJ; Weisz OA
Mol Genet Metab; 2014 Feb; 111(2):184-92. PubMed ID: 24215843
[TBL] [Abstract][Full Text] [Related]
7. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
[TBL] [Abstract][Full Text] [Related]
8. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
9. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
10. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
11. ZFN-mediated in vivo gene editing in hepatocytes leads to supraphysiologic α-Gal A activity and effective substrate reduction in Fabry mice.
Pagant S; Huston MW; Moreira L; Gan L; St Martin S; Sproul S; Holmes MC; Meyer K; Wechsler T; Desnick RJ; Yasuda M
Mol Ther; 2021 Nov; 29(11):3230-3242. PubMed ID: 33775910
[TBL] [Abstract][Full Text] [Related]
12. Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.
Namdar M; Gebhard C; Studiger R; Shi Y; Mocharla P; Schmied C; Brugada P; Lüscher TF; Camici GG
PLoS One; 2012; 7(4):e36373. PubMed ID: 22558451
[TBL] [Abstract][Full Text] [Related]
13. Precision medicine in Fabry disease.
Lenders M; Brand E
Nephrol Dial Transplant; 2021 Jun; 36(Suppl 2):14-23. PubMed ID: 34153986
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
15. Molecular basis of 1-deoxygalactonojirimycin arylthiourea binding to human α-galactosidase a: pharmacological chaperoning efficacy on Fabry disease mutants.
Yu Y; Mena-Barragán T; Higaki K; Johnson JL; Drury JE; Lieberman RL; Nakasone N; Ninomiya H; Tsukimura T; Sakuraba H; Suzuki Y; Nanba E; Mellet CO; García Fernández JM; Ohno K
ACS Chem Biol; 2014 Jul; 9(7):1460-9. PubMed ID: 24783948
[TBL] [Abstract][Full Text] [Related]
16. Migalastat HCl reduces globotriaosylsphingosine (lyso-Gb3) in Fabry transgenic mice and in the plasma of Fabry patients.
Young-Gqamana B; Brignol N; Chang HH; Khanna R; Soska R; Fuller M; Sitaraman SA; Germain DP; Giugliani R; Hughes DA; Mehta A; Nicholls K; Boudes P; Lockhart DJ; Valenzano KJ; Benjamin ER
PLoS One; 2013; 8(3):e57631. PubMed ID: 23472096
[TBL] [Abstract][Full Text] [Related]
17. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
18. The pharmacological chaperone 1-deoxygalactonojirimycin increases alpha-galactosidase A levels in Fabry patient cell lines.
Benjamin ER; Flanagan JJ; Schilling A; Chang HH; Agarwal L; Katz E; Wu X; Pine C; Wustman B; Desnick RJ; Lockhart DJ; Valenzano KJ
J Inherit Metab Dis; 2009 Jun; 32(3):424-40. PubMed ID: 19387866
[TBL] [Abstract][Full Text] [Related]
19. Substrate and Substrate-Mimetic Chaperone Binding Sites in Human α-Galactosidase A Revealed by Affinity-Mass Spectrometry.
Moise A; Maeser S; Rawer S; Eggers F; Murphy M; Bornheim J; Przybylski M
J Am Soc Mass Spectrom; 2016 Jun; 27(6):1071-8. PubMed ID: 27112153
[TBL] [Abstract][Full Text] [Related]
20. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
